Friday, 25 September 2026European Markets

ISEQ All Share Bullish Momentum With A 5% Rise In The Last 21 Sessions

Loading stream...

(VIANEWS) - ISEQ All Share (^ISEQ) has been up by 5.66% for the last 21 sessions. At 08:38 EST on Tuesday, 7 February, ISEQ All Share (^ISEQ) is $8,070.64.

Concerning ISEQ All Share's yearly highs and lows, it's 31.91% up from its 52-week low and 5.55% down from its 52-week high.

Volatility

ISEQ All Share's last week, last month's, and last quarter's current intraday variation average was 1.04%, 0.33%, and 0.75%, respectively.

ISEQ All Share's highest amplitude of average volatility was 1.16% (last week), 0.57% (last month), and 0.75% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ISEQ All Share's is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 6 February, "Tesla stock is up 2.1% in Monday's premarket to start the week near $194, while the NASDAQ futures market is off 0.8% as continued pessimism stemming from Friday's meteoric jobs number has renewed worries that higher interest rates will stick around longer in 2023. "
  • According to FXStreet on Monday, 6 February, "QCOM is listed on NASDAQ and is a component of Nasdaq 100 and S&P 500 under Information Technology."

More news about ISEQ All Share (^ISEQ).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com